NO20063468L - Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister - Google Patents

Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister

Info

Publication number
NO20063468L
NO20063468L NO20063468A NO20063468A NO20063468L NO 20063468 L NO20063468 L NO 20063468L NO 20063468 A NO20063468 A NO 20063468A NO 20063468 A NO20063468 A NO 20063468A NO 20063468 L NO20063468 L NO 20063468L
Authority
NO
Norway
Prior art keywords
receptor antagonists
glutamate receptor
triazole compounds
compounds
metabotrophic glutamate
Prior art date
Application number
NO20063468A
Other languages
English (en)
Norwegian (no)
Inventor
Tao Xin
Tomislav Stefanac
Louise Edwards
Methvin Isaac
Martin Johansson
Johan Malmberg
Alexander Minidis
Karin Staaf
Abdelmalik Slassi
David Wensbo
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063468(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of NO20063468L publication Critical patent/NO20063468L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20063468A 2004-02-18 2006-07-28 Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister NO20063468L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54528904P 2004-02-18 2004-02-18
PCT/US2005/005200 WO2005080379A1 (en) 2004-02-18 2005-02-17 Triazole compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
NO20063468L true NO20063468L (no) 2006-11-15

Family

ID=34886127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063468A NO20063468L (no) 2004-02-18 2006-07-28 Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister

Country Status (17)

Country Link
US (2) US20070185178A1 (ko)
EP (1) EP1720860A1 (ko)
JP (1) JP2007523178A (ko)
KR (1) KR20070027503A (ko)
CN (1) CN101018779A (ko)
AR (1) AR047744A1 (ko)
AU (1) AU2005214375A1 (ko)
BR (1) BRPI0507501A (ko)
CA (1) CA2554894A1 (ko)
EA (1) EA200601266A1 (ko)
IL (1) IL177057A0 (ko)
NO (1) NO20063468L (ko)
RU (1) RU2006127575A (ko)
TW (1) TW200604183A (ko)
UY (1) UY28760A1 (ko)
WO (1) WO2005080379A1 (ko)
ZA (1) ZA200606313B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080533A1 (ja) * 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811156A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
WO2009051556A1 (en) 2007-10-19 2009-04-23 Astrazeneca Ab Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
TW200922585A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mGluR5
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
US20100114146A1 (en) * 2008-10-30 2010-05-06 Albrecht Thomas E Methods and devices for predicting intra-gastric satiety and satiation creation device system performance
CA2745870A1 (en) * 2008-12-12 2010-06-17 Astrazeneca Ab A new process for preparing 4-[4-methyl-5-(c1-10alkylthio/c5-10aryl-c1-6alkylthio)-4h-1,2,4-triazol-3-yl]pyridines
US20110306768A1 (en) * 2008-12-18 2011-12-15 Astrazeneca Ab Processes for the manufacture of 3--pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-l,2,4-triazole, and (1r)-1-[2-(3-methylphenyl)-2h-tetrazol-5-yl]ethanol
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
WO2012062623A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
BR112015013350B1 (pt) 2012-12-20 2022-04-05 Tempest Therapeutics, Inc Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
PE20160608A1 (es) 2013-10-14 2016-07-08 Eisai Randd Man Co Ltd Compuestos de quinolina selectivamente sustituida
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
JP6618525B2 (ja) 2014-08-15 2019-12-11 ヤンセン ファーマシューティカルズ，インコーポレーテッド ピラゾール類
EA033197B1 (ru) 2015-07-09 2019-09-30 Янссен Фармацевтика Нв Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
MX2018009752A (es) 2016-02-10 2019-02-07 Janssen Pharmaceutica Nv 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
DK3860989T3 (da) 2018-10-05 2023-05-01 Forma Therapeutics Inc Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30)
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
PE20220386A1 (es) 2019-06-14 2022-03-18 Janssen Pharmaceutica Nv Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
BR112021025136A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b
CR20210615A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
AU2020292994A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4303109B2 (ja) * 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
CA2465207C (en) * 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
AU2003213783B2 (en) * 2002-03-12 2007-01-25 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
RU2352568C9 (ru) * 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5

Also Published As

Publication number Publication date
CA2554894A1 (en) 2005-09-01
EA200601266A1 (ru) 2007-02-27
UY28760A1 (es) 2005-06-30
TW200604183A (en) 2006-02-01
JP2007523178A (ja) 2007-08-16
CN101018779A (zh) 2007-08-15
AU2005214375A1 (en) 2005-09-01
EP1720860A1 (en) 2006-11-15
WO2005080379A1 (en) 2005-09-01
US20070185178A1 (en) 2007-08-09
IL177057A0 (en) 2006-12-10
AR047744A1 (es) 2006-02-15
BRPI0507501A (pt) 2007-06-26
ZA200606313B (en) 2007-03-28
KR20070027503A (ko) 2007-03-09
US20060019997A1 (en) 2006-01-26
RU2006127575A (ru) 2008-03-27

Similar Documents

Publication Publication Date Title
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
NO20071593L (no) Pyrimidinderivater
NO20055977L (no) Nye benzimidazolderivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20083582L (no) Pyridin-2-karboksamide derivater
NO20091141L (no) Pyrido (2,3-D) pyrimidinonforbindelser og deres anvendelse som P13 inhibitorer
NO20076648L (no) Novel thiophene derivatives
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20071504L (no) Pyrimidinderivanter.
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application